Following the FDA’s November announcement of an investigation into 20 cases of T cell lymphoma recipients of CAR-T therapies, a cadre of cancer and cell therapy leaders published their assessment in Nature.
Following the FDA’s November announcement of an investigation into 20 cases of T cell lymphoma recipients of CAR-T therapies, a cadre of cancer and cell therapy leaders published their assessment in Nature.